← Back to Search

Janus Kinase (JAK) Inhibitor

Deucravacitinib for Psoriasis (POETYK PSO-LTE Trial)

Phase 3
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women must not be pregnant, lactating, or breastfeeding
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 244 weeks
Awards & highlights

POETYK PSO-LTE Trial Summary

This trial will study the long-term safety and effectiveness of the drug Deucravacitinib in people who have previously taken it for psoriasis in a different trial.

Who is the study for?
This trial is for people who have completed a prior Phase 3 study of BMS-986165 for moderate-to-severe psoriasis. Women participants should not be pregnant, breastfeeding, or lactating. Individuals with any condition that could interfere with the study or those showing active symptoms of tuberculosis are excluded.Check my eligibility
What is being tested?
The focus is on Deucravacitinib (BMS-986165), assessing its long-term safety and effectiveness in individuals who've previously taken part in a related Phase 3 trial for treating psoriasis.See study design
What are the potential side effects?
While specific side effects aren't listed here, they may include typical drug reactions such as skin irritation at the application site, headaches, nausea, and potential immune system impacts since it's being used to treat psoriasis.

POETYK PSO-LTE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am not pregnant, lactating, or breastfeeding.

POETYK PSO-LTE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 244 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 244 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Adverse Events (AEs)
Incidence of Serious Adverse Events (SAEs)
Secondary outcome measures
Psoriasis Area and Severity Index (PASI) 75 response
static Physician Global Assessment (sPGA) 0/1 response

Side effects data

From 2022 Phase 3 trial • 220 Patients • NCT04167462
18%
Upper respiratory tract infection
8%
Mouth ulceration
7%
Nasopharyngitis
5%
Pruritus
5%
Headache
3%
Folliculitis
3%
Psoriasis
1%
Cholecystitis
1%
Gastroenteritis shigella
1%
Gastroenteritis
1%
Pharyngitis
1%
Diabetes mellitus
1%
Accidental overdose
1%
Hepatobiliary procedural complication
1%
Psoriatic arthropathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo Week 0 up to Week 16
BMS-986165 Week 0 up to Week 52
BMS-986165 Week 16 up to Week 52

POETYK PSO-LTE Trial Design

1Treatment groups
Experimental Treatment
Group I: BMS-986165Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986165
2020
Completed Phase 3
~2990

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,629 Previous Clinical Trials
4,125,084 Total Patients Enrolled
35 Trials studying Psoriasis
18,028 Patients Enrolled for Psoriasis

Media Library

Deucravacitinib (BMS-986165) (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04036435 — Phase 3
Psoriasis Research Study Groups: BMS-986165
Psoriasis Clinical Trial 2023: Deucravacitinib (BMS-986165) Highlights & Side Effects. Trial Name: NCT04036435 — Phase 3
Deucravacitinib (BMS-986165) (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04036435 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the desired sample size for this clinical trial?

"As of right now, this trial does not have any open slots for new participants. According to the information provided by clinicaltrials.gov, the last time this study was edited was on July 1st, 2022. However, if you are looking for other studies to participate in, there are presently 179 clinical trials actively recruiting participants with psoriasis and 11 studies for BMS-986165 actively recruiting participants."

Answered by AI

Are there other instances of BMS-986165 being trialed?

"H-T. Centrum Medyczne Spolka z Ograniczona Odpowiedzialnoscia first studied BMS-986165 in 2018 and, to date, there are 34 completed studies. 11 clinical trials using this medication are ongoing with a large proportion taking place in Stony Brook, New york."

Answered by AI

What have been the side effects observed in individuals taking BMS-986165?

"BMS-986165 is in Phase 3 of clinical trials, meaning that there is efficacy data as well as multiple rounds of safety data. Therefore, it received a score of 3 for safety."

Answered by AI

Has this research been done before?

"BMS-986165 has been investigated in clinical trials since 2018. The first trial, sponsored by Bristol-Myers Squibb concluded that year and involved 240 patients. Phase 2 approval was granted after the successful completion of this initial study. Currently, 11 ongoing trials are being conducted in 400 locations across 36 countries."

Answered by AI

In how many different medical institutions is this research being conducted?

"Local Institution - 0218 in Stony Brook, New york, LCC Medical Research in Miami, Florida, Marietta Dermatology & The Skin cancer Center in Marietta, Georgia are some of the 67 sites running this study."

Answered by AI

Are we looking for more participants in this trial at the moment?

"According to the latest information available on clinicaltrials.gov, this trial is no longer recruiting patients. Although the study's last update was on July 1st, 2022, it is not presently looking for any more participants. There are however, 190 other trials that are still enrolling individuals."

Answered by AI

Who else is applying?

What state do they live in?
Florida
What portion of applicants met pre-screening criteria?
Met criteria
~472 spots leftby Jul 2026